Lobe Sciences (TSE:LOBE)
:LOBE
Top Page
Lobe Sciences
(LOBE)
Select Model
Select Model
Rating:47Neutral
Price Target:
C$0.06
▲(6.67% Upside)
Action:ReiteratedDate:03/28/26
The score is primarily held back by very weak financial performance (near-zero TTM revenue, persistent losses, and ongoing cash burn), which raises sustainability and funding-risk concerns. Technicals provide a partial offset with mildly positive momentum and price above longer-term averages, but valuation remains challenged due to negative earnings and no dividend support.
Positive Factors
Modest leverage
Low absolute debt and a debt-to-equity near 0.19 materially reduce near-term balance-sheet pressure for a pre-revenue developer. This gives management more optionality for staged R&D spending or negotiating financing on less dilutive terms versus a highly leveraged peer.
Negative Factors
Near-zero revenue
Effectively zero trailing revenue and multi-million-dollar operating losses show the company is not yet at commercial scale. Persistent unprofitability undermines internal funding capability, increases reliance on external capital, and heightens execution risk over the 2–6 month horizon.
Read all positive and negative factors
Positive Factors
Negative Factors
Modest leverage
Low absolute debt and a debt-to-equity near 0.19 materially reduce near-term balance-sheet pressure for a pre-revenue developer. This gives management more optionality for staged R&D spending or negotiating financing on less dilutive terms versus a highly leveraged peer.
Read all positive factors
Lobe Sciences (LOBE) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$17.52M
Dividend YieldN/A
Average Volume (3M)19.65K
Price to Earnings (P/E)―
Beta (1Y)0.09
Revenue Growth-100.00%
EPS Growth-8.70%
CountryCA
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)N/A
Shares Outstanding269,487,120
10 Day Avg. Volume13,139
30 Day Avg. Volume19,648
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)2.94
Price to Sales (P/S)0.00
P/FCF Ratio-4.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Lobe Sciences Business Overview & Revenue Model
Company Description
Lobe Sciences Ltd., a life sciences company, focuses on the research and development of psychedelic medicines. It develops psilocybin-based therapeutics in combination with N-acetylcysteine for the treatment of mild traumatic brain injuries and po...
How the Company Makes Money
null...
Lobe Sciences Financial Statement Overview
Summary
Income Statement
9
Very Negative
Balance Sheet
38
Negative
Cash Flow
12
Very Negative
| Breakdown | Nov 2025 | Nov 2024 | Aug 2023 | Nov 2022 | Nov 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 136.21K | 840.53K | 0.00 | 0.00 |
| Gross Profit | 0.00 | 134.45K | 772.83K | -10.22K | 0.00 |
| EBITDA | -4.27M | -4.12M | -4.40M | -11.96M | -6.16M |
| Net Income | -4.43M | -4.42M | -4.71M | -12.25M | -22.82M |
Balance Sheet | |||||
| Total Assets | 7.59M | 258.57K | 2.30M | 1.75M | 12.10M |
| Cash, Cash Equivalents and Short-Term Investments | 7.54M | 237.77K | 140.29K | 907.54K | 7.43M |
| Total Debt | 273.35K | 1.75M | 332.64K | 0.00 | 0.00 |
| Total Liabilities | 2.70M | 3.37M | 2.46M | 1.30M | 804.70K |
| Stockholders Equity | 2.36M | -3.11M | -160.13K | 445.69K | 11.29M |
Cash Flow | |||||
| Free Cash Flow | -1.42M | -462.29K | -1.72M | -2.73M | -5.04M |
| Operating Cash Flow | -1.42M | -462.29K | -1.72M | -2.73M | -5.04M |
| Investing Cash Flow | 6.56M | 0.00 | 0.00 | 1.74M | 1.07M |
| Financing Cash Flow | 514.40K | 563.51K | 950.01K | 753.12K | 4.92M |
Lobe Sciences Technical Analysis
Neutral
0.06
Price Trends
0.06
Positive
0.05
Positive
0.05
Positive
Market Momentum
<0.01
Negative
49.45
Neutral
38.89
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:LOBE, the sentiment is Neutral. The current price of 0.06 is below the 20-day moving average (MA) of 0.07, above the 50-day MA of 0.06, and above the 200-day MA of 0.05, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 49.45 is Neutral, neither overbought nor oversold. The STOCH value of 38.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:LOBE.
Lobe Sciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | C$9.29M | 8.94 | 11.57% | ― | -1.14% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | C$17.52M | -2.55 | ― | ― | -100.00% | -8.70% | |
46 Neutral | C$18.85M | -5.08 | -68.32% | ― | 2.41% | 74.61% | |
45 Neutral | C$27.35M | -3.68 | -19.10% | ― | 18.06% | 34.58% | |
45 Neutral | C$10.00M | 5.19 | ― | ― | 15.64% | 58.47% | |
41 Neutral | C$23.91M | -44.16 | -2.15% | ― | 19.66% | 84.34% |
* Healthcare Sector Average
TSE:LOBE
Lobe Sciences
0.07
0.04
116.67%
TSE:LABS
MediPharm Labs
0.07
-0.04
-35.00%
TSE:PCLO
PharmaCielo
0.07
<0.01
8.33%
TSE:OILS
Nextleaf Solutions
0.06
>-0.01
-8.33%
TSE:AVCN
Avicanna
0.15
-0.18
-53.85%
TSE:GWAY
Greenway Greenhouse Cannabis Corp.
0.18
-0.03
-14.29%
Lobe Sciences Corporate Events
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Lobe Sciences Strengthens Balance Sheet and Adopts Subsidiary Model to Cut Dilution
Positive
Mar 25, 2026
Lobe Sciences has sharply improved its financial position since August 2024, slashing liabilities by 81%, cutting outstanding warrants by about 70% and boosting cash reserves from under $0.3 million to nearly $6 million. Total assets and net worki...
Business Operations and StrategyExecutive/Board Changes
Lobe Sciences Names Mirza Rahimani as Chief Financial Officer
Positive
Mar 9, 2026
Lobe Sciences has promoted Mirza Rahimani to Chief Financial Officer, effective March 2, 2026, after he had been providing financial advisory services to management and the board since December 2025. Rahimani replaces former CFO Yong Yao, who serv...
Business Operations and StrategyFinancial Disclosures
Lobe Sciences Ramps Up R&D on Psilocin-Based Therapeutic as Cash Position Remains Solid
Positive
Feb 3, 2026
Lobe Sciences reported first-quarter fiscal 2026 results showing a sharp ramp-up in research and development spending to approximately $982,000 as it accelerated work on lead candidate L-130 through its Cynaptec subsidiary, while maintaining a cas...
Business Operations and StrategyExecutive/Board Changes
Lobe Sciences Bolsters Board with Capital Markets Expert as It Builds on 2025 Momentum
Positive
Jan 13, 2026
Lobe Sciences has strengthened its board of directors with the appointment of corporate and securities lawyer Nick Karakochuk, whose expertise in mergers and acquisitions, capital markets, and governance is expected to support the company’s ...
Business Operations and StrategyExecutive/Board ChangesFinancial Disclosures
Lobe Sciences Strengthens Balance Sheet and Refocuses Pipeline After Leadership Overhaul
Positive
Jan 6, 2026
Lobe Sciences reported a substantial improvement in its fiscal 2025 financial position following a leadership transition and board renewal, with cash rising to $5.9 million, new short-term investments of $1.7 million, and working capital swinging ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.